ClinicalTrials.gg
CompletedNCT00594386SP715Updated Oct 2, 2014Results posted

An Open-Label Extension Trial to Assess the Safety of Long-Term Treatment of Rotigotine in Advance-Stage Parkinson's Disease

A Phase 3 interventional study of Rotigotine in Parkinson's Disease, sponsored by UCB Pharma. Completed at 41 sites in 2 countries. Open to participants aged 31 Years and older. Per ClinicalTrials.gov, last updated 2014-10-02.

Sponsored by UCB Pharma (part of UCB S.A.) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
258
Allocation
Not applicable
Ages
31 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 44 studies testing rotigotine in Parkinson Disease — 1 open to participants now, 1 under way, none of them phase 3. rotigotine · Parkinson Disease.

Enrollment
11th of 42
258 · median 123
Started
2002
with 2 others
Phase 3
20 of 44
none open now
Registered
16th of 44
by date
Lead sponsor
22 of 44
UCB Pharma

Among the 44 studies testing rotigotine in Parkinson Disease, this one is the 11th largest by enrollment of the 42 interventional ones that give a count, is one of 3 that started in 2002, is one of 20 in phase 3, and was the 16th registered.

Parkinson Disease

4,578 studies on the registry are indexed under Parkinson Disease; 1,085 are open to participants now.

Browse Parkinson Disease studies →

Open to participants now

1 of the 44 studies testing rotigotine in Parkinson Disease is open now. Recruiting first, the newest first:

About rotigotine

rotigotine: first FDA approval 2007 (NEUPRO), first EMA approval 2006. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 748 Parkinson Disease studies recruiting now, 311 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 189 take healthy volunteers.

This study: 31 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 44 studies testing rotigotine in Parkinson Disease, or all of them as a file.
02

Study summary

The objective of this open-label extension is to assess the safety and tolerability of long-term treatment of the Rotigotine patch in subjects with advanced-stage idiopathic Parkinson's Disease.

Read the detailed description

This is the open-label extension to the randomized, double-blind, placebo-controlled SP650 trial that assessed the efficacy and safety and tolerability of the Rotigotine patch in subjects with advanced-stage idiopathic Parkinson's Disease who are not well-controlled on Levodopa.

03

Conditions studied

  • Parkinson's Disease

Browse trials for

Keywords

  • Rotigotine
  • Neupro
04

Who can participate

Ages eligible
31 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects who have completed six months of maintenance treatment in the SP650 double-blind trial

Exclusion criteria

Exclusion Criteria:

  • Subjects who had an ongoing serious adverse event from the SP650 double-blind trial that was assessed as related to study medication
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
258 participants (actual)

Study arms

  • Experimental
    Rotigotine

    Drug: Rotigotine

Interventions

  • Rotigotine transdermal patches: 10 cm2 (2 mg/24 hours); 20 cm2 (4 mg/24 hours); 30 cm2 (6 mg/24 hours); 40 cm2 (8 mg/24 hours) Optimal dosing: During the first year: The maximum Rotigotine dose allowed is 6 mg/24 hours. After the first year: Allowed dose increase of Rotigotine up to a maximum of 16 mg/24 hours.

    Also known as: Neupro

06

What researchers measure

Primary outcomes

  1. Number of Subjects With at Least One Adverse Event During This Open-label Extension Study

    Adverse events are any untoward medical occurrences in a subject administered study treatment, whether or not these events are related to treatment.

    Time frame: 6 years

Secondary outcomes

  1. Number of Subjects Who Withdrew From the Trial Due to an Adverse Event.

    Adverse events are any untoward medical occurrences in a subject administered study treatment, whether or not these events are related to treatment.

    Time frame: 6 years

  2. Mean Epworth Sleepiness Scale Score During the Open-label Extension.

    The Epworth Sleepiness Scale (ESS) is a self-administered questionnaire with 8 questions. The total ESS score is the sum of 8 item-scores and can range between 0 and 24. The higher the score, the higher the person's level of daytime sleepiness.

    Time frame: Visit 11 (end of year 1), Visit 15 (end of year 2), Visit 19 (end of year 3), Visit 23 (end of year 4), Visit 27 (end of year 5), Visit 31 (end of year 6), End of Treatment (last study visit or early withdrawal visit)

07

Results

Posted Dec 18, 2009

Participant flow

A multicenter Open-Label Extension Trial to Assess the Safety of Long-Term Treatment of Rotigotine in Advanced-Stage Parkinson's Disease with 41 sites in United States and Canada from August 2002 to December 2008

Participant flow — Overall Study
MilestoneRotigotine
Started258
Completed0
Not completed258
Withdrew: Major protocol violation2
Withdrew: Lack of efficacy12
Withdrew: Adverse event68
Withdrew: Unsatisfactory compliance of subject11
Withdrew: Subject withdrew consent35
Withdrew: Study ended per sponsor115
Withdrew: Lost to follow-up6
Withdrew: Other: patient went off patch (hospital)1
Withdrew: Other: subject moved to seattle1
Withdrew: Other: subject admitted to nursing home1
Withdrew: Other: study terminated per investigator2
Withdrew: Other: sponsor closure of study1
Withdrew: Other: site terminated participation1
Withdrew: Other: patient wants prescription neupro1
Withdrew: Other: loss of drivers license1

Outcome measures

PrimaryNumber of Subjects With at Least One Adverse Event During This Open-label Extension Study

Adverse events are any untoward medical occurrences in a subject administered study treatment, whether or not these events are related to treatment.

Time frame:
6 years
Reported as:
Number · Subjects
Number of Subjects With at Least One Adverse Event During This Open-label Extension Study
SubjectsRotigotine
Number of Subjects With at Least One Adverse Event During This Open-label Extension Study258
SecondaryNumber of Subjects Who Withdrew From the Trial Due to an Adverse Event.

Adverse events are any untoward medical occurrences in a subject administered study treatment, whether or not these events are related to treatment.

Time frame:
6 years
Reported as:
Number · Subjects
Number of Subjects Who Withdrew From the Trial Due to an Adverse Event.
SubjectsRotigotine
Number of Subjects Who Withdrew From the Trial Due to an Adverse Event.68
SecondaryMean Epworth Sleepiness Scale Score During the Open-label Extension.

The Epworth Sleepiness Scale (ESS) is a self-administered questionnaire with 8 questions. The total ESS score is the sum of 8 item-scores and can range between 0 and 24. The higher the score, the higher the person's level of daytime sleepiness.

Time frame:
Visit 11 (end of year 1), Visit 15 (end of year 2), Visit 19 (end of year 3), Visit 23 (end of year 4), Visit 27 (end of year 5), Visit 31 (end of year 6), End of Treatment (last study visit or early withdrawal visit)
Reported as:
Mean · Score on a scale
Mean Epworth Sleepiness Scale Score During the Open-label Extension.
Score on a scaleRotigotine
Visit 11 (end of year 1) (n=254)8.6 ± 4.9
Visit 15 (end of year 2) (n=254)8.9 ± 4.9
Visit 19 (end of year 3) (n=254)9.3 ± 5.1
Visit 23 (end of year 4) (n=254)9.8 ± 5.2
Visit 27 (end of year 5) (n=254)9.7 ± 5.3
Visit 31 (end of year 6) (n=254)10.0 ± 5.4
End of Treatment (n=258)10.0 ± 5.4

Adverse events

Collected over Up to 6 years. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Rotigotine—165/258 (64%)253/258 (98.1%)
Most frequent serious events
Showing 10 of 202
Most frequent serious events
EventRotigotine
Parkinson's diseaseNervous system disorders25/258
FallInjury, poisoning and procedural complications13/258
Chest painGeneral disorders10/258
DehydrationMetabolism and nutrition disorders9/258
Urinary tract infectionInfections and infestations8/258
Cerebrovascular accidentNervous system disorders8/258
SyncopeNervous system disorders8/258
HallucinationPsychiatric disorders8/258
Cardiac failure congestiveCardiac disorders7/258
CellulitisInfections and infestations7/258
Most frequent other events
Showing 10 of 53
Most frequent other events
EventRotigotine
SomnolenceNervous system disorders150/258
FallInjury, poisoning and procedural complications100/258
Oedema peripheralGeneral disorders80/258
NauseaGastrointestinal disorders61/258
DizzinessNervous system disorders61/258
ArthralgiaMusculoskeletal and connective tissue disorders60/258
ConstipationGastrointestinal disorders58/258
InsomniaPsychiatric disorders56/258
Urinary tract infectionInfections and infestations55/258
HallucinationPsychiatric disorders54/258

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Rotigotine
<=18 years0
Between 18 and 65 years98
>=65 years160
Age, Continuous
Age, Continuous(years)Rotigotine
Mean66.4 ± 9.6
Sex: Female, Male
Sex: Female, Male(Participants)Rotigotine
Female85
Male173
Region of Enrollment
Region of Enrollment(participants)Rotigotine
United States243
Canada15
08

Study locations

41 sites
  • Huntsville, Alabama, United States
  • Peoria, Arizona, United States
  • Phoenix, Arizona, United States
  • Tucson, Arizona, United States
  • Hot Springs, Arkansas, United States
  • Fountain Valley, California, United States
  • Fresno, California, United States
  • Irvine, California, United States
  • Los Angeles, California, United States
  • Danbury, Connecticut, United States
  • Fairfield, Connecticut, United States
  • New Haven, Connecticut, United States
  • Miami, Florida, United States
  • Pompano Beach, Florida, United States
  • St. Petersburg, Florida, United States
  • Sunrise, Florida, United States
  • Atlanta, Georgia, United States
  • Hoffman Estates, Illinois, United States
  • Fort Wayne, Indiana, United States
  • Kansas City, Kansas, United States
  • Lexington, Kentucky, United States
  • Boston, Massachusetts, United States
  • Southfield, Michigan, United States
  • Minneapolis, Minnesota, United States
  • Henderson, Nevada, United States
  • Albany, New York, United States
  • Forest Hills, New York, United States
  • Louisville, New York, United States
  • Asheville, North Carolina, United States
  • Raleigh, North Carolina, United States
  • Toledo, Ohio, United States
  • Upland, Pennsylvania, United States
  • Houston, Texas, United States
  • San Antonio, Texas, United States
  • Richmond, Virginia, United States
  • Roanoke, Virginia, United States
  • Milwaukee, Wisconsin, United States
  • Edmonton, Alberta, Canada
  • Ottawa, Ontario, Canada
  • Montrél, Quebec, Canada
  • Saskatoon, Saskatchewan, Canada
09

References and documents

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2002, a primary completion of Dec 2008 and a completion of Dec 2008. It does not say whether these dates are actual or estimated.

Results were first posted in Dec 2009, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 24, 2007
First posted
Jan 15, 2008
Start
Aug 2002
Primary completionActual
Dec 2008
CompletionActual
Dec 2008
Results first posted
Dec 18, 2009
Last update
Oct 2, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 2, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00594386
Lead sponsor
UCB Pharma
Responsible party
Sponsor
First posted
Jan 15, 2008
Start date
Aug 2002
Primary completion
Dec 2008
Completion
Dec 2008
Results posted
Dec 18, 2009
Last update
Oct 2, 2014

Study contacts

UCB Clinical Trial Call Center
study director · +1 877 822 9493 (UCB)

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2010. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Rotigotine

Start the discussion